Contineum Therapeutics, Inc. 8K

Contineum Therapeutics reported that its partner Johnson & Johnson’s Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 for major depressive disorder failed to meet its primary efficacy endpoint, though safety was acceptable and further data analysis is ongoing.

On September 14, 2026, Contineum Therapeutics, Inc. announced that the Phase 2 MOONLIGHT-1 proof-of-concept trial evaluating JNJ-5120/PIPE-307, an M1 receptor inhibitor licensed to and being developed by Johnson & Johnson for major depressive disorder, did not meet its primary efficacy endpoint of change from baseline in MADRS total score at Day 5 versus placebo, although the drug was well-tolerated with no new safety signals; Johnson & Johnson is continuing to analyze the Phase 2 data, including prespecified exploratory endpoints, to determine the clinical relevance of the findings and inform next steps for the program, while Contineum highlighted the associated development risks and broader uncertainties in its forward-looking statements.

Filing Facts

CIK

1855175

Ticker

CTNM

Form

8K

Source Type

fda

Accession

0001628280-26-061834

Alert Tier

6